Roots Analysis

JANUARY 23, 2024

Moreover, these short chains of amino acids, distinct from proteins in their shorter length, serve as essential building blocks for various scientific investigations. Additionally, peptides may offer enhanced absorption compared to proteins, swiftly entering the bloodstream by easily permeating the skin and intestines.

Development 40

Development Contract Manufacturing Drugs Manufacturing 40

Drug Discovery World

DECEMBER 14, 2023

The new hub will become a part of the already thriving life sciences sector in the Glasgow area, most of which is centred around the university, the Cancer Research UK Scotland Institute and the BioCity cluster, making Glasgow and its surrounds one of the most important regions for drug discovery and development in the UK.

Drugs 75

Drugs Life Science Research Scientist 75

XTalks

JANUARY 29, 2021

They are both checkpoint inhibitors targeted towards programmed cell death protein 1 (PD-1 inhibitors), a protein that is responsible for downregulating the immune system and preventing it from killing cancer cells. As both products target the same pathway, they naturally compete in many indications (Table 1).

Clinical Trials 104

Clinical Trials Clinical Trials Production Trials 104

XTalks

FEBRUARY 27, 2024

TIL vs CAR T-Cell Therapies While CAR T-cell therapies involve inserting a CAR engineered to target a specific cancer cell protein into a patient’s T cells, TIL-based T-cell therapies like Amtagvi involve separating TILs from a patient’s tumor (in autologous therapies) and expanding them ex vivo.

FDA Approval 52

FDA Approval Manufacturing In-Vivo Trials 52

XTalks

JANUARY 23, 2024

This venture also led me to identify a gap in the market for contract manufacturing of recombinant proteins. Together, we developed the world’s first growth hormone receptor antagonist, Somavert (pegvisomant), targeting acromegaly.

Development 72

Development Hormones Drugs Trials 72

XTalks

APRIL 11, 2024

Moreover, rather than producing antibodies, the cancer cells produce abnormal proteins that can cause complications. In last month’s call, Legend CEO Ying Huang, PhD, shared that the partners are aiming to increase manufacturing capacity at their New Jersey plant.

FDA Approval 52

FDA Approval Manufacturing Trials Clinical Trials 52

The Pharma Data

DECEMBER 23, 2020

Cellular (T cell) response were observed to multiple regions of the spike protein including the RBD region. . The 1.0 mg and 2.0 mg dose group both demonstrated seroconversion in 95% of the subjects, respectively, with 78% demonstrating neutralizing antibodies in the 1.0 mg dose group.

DNA 40

DNA Vaccination Vaccine Immune Response 40